| Literature DB >> 35712354 |
Bruno Amorim-Carmo1, Adriana M S Parente1, Eden S Souza2, Arnóbio A Silva-Junior1, Renata M Araújo1, Matheus F Fernandes-Pedrosa1.
Abstract
The rapid development of multidrug-resistant pathogens against conventional antibiotics is a global public health problem. The irrational use of antibiotics has promoted therapeutic limitations against different infections, making research of new molecules that can be applied to treat infections necessary. Antimicrobial peptides (AMPs) are a class of promising antibiotic molecules as they present broad action spectrum, potent activity, and do not easily induce resistance. Several AMPs from scorpion venoms have been described as a potential source for the development of new drugs; however, some limitations to their application are also observed. Here, we describe strategies used in several approaches to optimize scorpion AMPs, addressing their primary sequence, biotechnological potential, and characteristics that should be considered when developing an AMP derived from scorpion venoms. In addition, this review may contribute towards improving the understanding of rationally designing new molecules, targeting functional AMPs that may have a therapeutic application.Entities:
Keywords: analog peptides; antimicrobial activity; hemolytic activity; scorpion peptides; structural modification
Year: 2022 PMID: 35712354 PMCID: PMC9197468 DOI: 10.3389/fmolb.2022.887763
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
FIGURE 1Sequence alignment of 10 scorpion antimicrobial peptides. *Conserved residues.
FIGURE 2Theoretical tridimensional structure using UCSF Chimera software (Pettersen et al., 2004) for the peptides IsCT (A) and Stigmurin (C). In (B,D) peptides IsCT and Stigmurin in electrostatic surface, respectively. Light blue and dark blue represent hydrophilic and hydrophobic regions, respectively.
Physicochemical characteristics of native antimicrobial peptides and scorpion analogs.
| Scorpion | Native peptide | H | µH | Z | Analog peptide | Residue substitution | H | µH | Z | References |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| 0.89 | 0.57 | +2 |
| Ser and Gly by Lys | 0.78 | 0.66 | +3 |
|
|
| 0.72 | 0.72 | +4 | |||||||
|
| Ser and Gly by Lys | 0.73 | 0.70 | +5 |
| |||||
|
| Ser and Gly by Lys | 0.61 | 0.80 | +7 | ||||||
|
|
| 0.82 | 0.58 | +2 |
| Gly by Lys | 0.74 | 0.64 | +3 |
|
|
| Asn by Lys | 0.79 | 0.60 | +3 | ||||||
|
| Ser by Lys | 0.75 | 0.63 | +3 | ||||||
|
| Ala by Glu | 0.75 | 0.61 | +1 | ||||||
|
| Asn by Glu | 0.82 | 0.58 | +1 | ||||||
|
| Ala by Trp | 0.97 | 0.72 | +2 | ||||||
|
| Ala by Glu and Trp | 0.90 | 0.76 | +1 | ||||||
|
|
| 0.84 | 0.76 | +2 |
| Arg and Ser by Lys | 0.77 | 0.80 | +3 |
|
|
| Arg by Leu | 0.83 | 0.75 | +2 | ||||||
|
| Ile and Leu by Val | 0.76 | 0.68 | +2 | ||||||
|
| Ile and Leu by Ala | 0.62 | 0.55 | +2 | ||||||
|
| 0.87 | 0.63 | +1 |
| Ala by Lys | 0.77 | 0.64 | +2 | ||
|
| Ile and Val by Leu and Lys | 0.48 | 0.35 | +3 | ||||||
|
|
| 0.90 | 0.43 | +1 |
| His by Lys | 0.84 | 0.49 | +2 |
|
|
| Pro and His by Arg and Lys | 0.74 | 0.51 | +3 |
| |||||
|
| Ser, His, Gly, and Ala by Lys | 0.61 | 0.61 | +6 |
| |||||
|
|
| 0.78 | 0.77 | +1 |
| Ile by Lys | 0.55 | 0.56 | +1 |
|
|
| Ile by Val | 0.69 | 0.69 | +1 | ||||||
|
| Ile by Leu | 0.76 | 0.76 | +1 | ||||||
|
| Glu by Lys | 0.75 | 0.80 | +3 | ||||||
|
| Lys by Glu | 0.71 | 0.76 | −1 | ||||||
|
| 0.89 | 0.71 | +1 |
| Ile by Ala | 0.65 | 0.49 | +1 | ||
|
| Ile by Val | 0.79 | 0.62 | +1 | ||||||
|
|
| 0.78 | 0.43 | +2 |
| Ser, Ile, and Gly by Lys | 0.66 | 0.75 | +6 |
|
|
| 0.90 | 0.51 | +2 |
| Ser and Gly by Lys | 0.67 | 0.73 | +6 | ||
|
|
| 0.68 | 0.67 | +1 |
| Removal of Gly and Phe | 0.65 | 0.69 | +1 |
|
|
| Gly by Lys | 0.58 | 0.76 | +2 | ||||||
|
| Trp by Leu | 0.52 | 0.75 | +2 | ||||||
|
| Glu by Lys | 0.49 | 0.78 | +4 | ||||||
|
| Gly by Lys | 0.41 | 0.76 | +5 | ||||||
|
| Ser by Lys | 0.33 | 0.83 | +6 | ||||||
|
|
| 0.90 | 0.43 | +2 |
| Ser and His by Lys | 0.68 | 0.64 | +6 |
|
|
| 0.85 | 0.47 | +2 |
| Ser and Asn by Lys | 0.67 | 0.63 | +6 | ||
|
|
| 0.54 | 0.48 | +3 |
| Pro by Gly | 0.51 | 0.49 | +3 |
|
|
| Addition and substitution of Pro, Ser, and Leu by Gly and Pro | 0.49 | 0.28 | +3 | ||||||
|
|
| 0.84 | 0.45 | +2 |
| Ser, Ala, and Asn by Ala and Lys | 0.61 | 0.66 | +7 |
|
|
| 0.80 | 0.42 | +2 |
| Ser, Ala, and Asn by Val and Lys | 0.56 | 0.64 | +7 | ||
|
|
| 0.88 | 0.46 | +1 |
| Ser by Lys | 0.72 | 0.57 | +4 |
|
|
| Ser and Gly by Lys | 0.56 | 0.62 | +7 | ||||||
|
|
| 0,29 | 0,081 | +4 and +5 |
| Sequence combination | 0,17 | 0,50 | +8 |
|
|
| Sequence combination | 0,27 | 0,63 | +6 | ||||||
|
| Sequence combination | 0,29 | 0,61 | +5 |
H, hydrophobicity; µH, hydrophobicity moment; Z, net charge.
Modifications in analog peptides are marked in bold.
Not calculated by the authors of the studies (calculated here using the HeliQuest server).
Comparison of hemolytic and antimicrobial activities of native scorpion peptides and their analogs after modifications.
| Native peptide | Hemolytic activity | MIC | Analog peptide | Hemolytic activity | MIC | Strains | References |
|---|---|---|---|---|---|---|---|
| Stigmurin | 1.17% in 75 µM | >150; 9.3 and 37.5 µM | StigA6 | 30% in 75 µM | 4.6; 2.3 and 9.3 µM |
|
|
| StigA16 | 30% in 75 µM | 2.3; 2.3 and 4.6 µM | |||||
| StigA25 | 30% in 18.8 µM | 2.3; 1.2 and 9.4 µM |
|
| |||
| StigA31 | 30% in 18.8 µM | 1.2; 2.3 and 4.7 µM | |||||
| VmCT1 | Not calculated for 30% | 0.78; 3.12 and 12.5 µM | [K]3-VmCT1-NH2 | Not calculated for 30% | 0.39; 3.12 and 3.12 µM |
|
|
| [K]7-VmCT1-NH2 | Not calculated for 30% | 0.39; 1.56 and 1.56 µM | |||||
| [K]11-VmCT1-NH2 | Not calculated for 30% | 0.39; 1.56 and 1.56 µM | |||||
| [E]4-VmCT1-NH2 | Not calculated for 30% | 3.12; 50 and 50 µM | |||||
| [E]7-VmCT1-NH2 | Not calculated for 30%M | 0.78; 6.25 and 12.5 µM | |||||
| [W]9-VmCT1-NH2 | Not calculated for 30% | 0.78; 1.56 and 1.56 µM | |||||
| [E]4[W]9-VmCT1-NH2 | 1.6 µM | 3.12; 12.5 and 6.25 µM | |||||
| AamAP1 | ∼30% in 100 µM | 150; 20 and 64 µM | AamAP-S1 | ∼30% in 40 µM | 5; 3 and 5 µM |
|
|
| 20 µM | A3 | ∼30% in 40 µM | 5 µM |
|
| ||
| 20 and 150 µM | AamAP1-Lysine | ∼30% in 80 µM | 5 and 7.5 µM |
|
| ||
| IsCT1 | 30% in ∼20 μg/ml | 50; >100 and 50 μg/ml | IsCT1A1 | ∼5% in 100 μg/ml | >100; >100 and >100 μg/ml |
|
|
| IsCT1V1 | ∼5% in 100 μg/ml | >100; >100 and >100 μg/ml | |||||
| IsCT1L1 | 30% in ∼20 μg/ml | 50; >100 and 50 | |||||
| IsCT1K7 | 30% in ∼30 μg/ml | 100; >100 and >100 μg/ml | |||||
| IsCT1E7 | 0% in 100 μg/ml | >100; >100 and >100 μg/ml | |||||
| IsCT2 | 30% in ∼20 μg/ml | 50; 100 and 50 μg/ml | IsCT2A1 | ∼5% in 100 μg/ml | >100; >100 and >100 μg/ml | ||
| IsCT2V1 | ∼20% in 100 μg/ml | >100; >100 and >100 μg/ml | |||||
| TsAP-1 | ∼5% in 160 µM | 120; 160 and 160 µM | TsAP-S1 | 30% in ∼6 µM | 2.5; 5 and 2.5 µM |
|
|
| TsAP-2 | 30% in ∼30 µM | 5; >320 and 10 µM | TsAP-S2 | 30% in ∼6 µM | 5; 5 and 2.5 µM | ||
| Hp1404 | 30% in ∼40 µM | 12.5 µM | Hp1404-T1 | N/C | >25 µM |
|
|
| Hp1404-T1a | N/C | >25 µM | |||||
| Hp1404-T1b | N/C | >25 µM | |||||
| Hp1404-T1c | N/C | 3.13 µM | |||||
| Hp1404-T1d | N/C | 1.56 µM | |||||
| Hp1404-T1e | 0% in 200 µM | 1.56 µM | |||||
| AcrAP1 | Not calculated for 30% | 8; >250 and 16 µM | AcrAP1a | Not calculated for 30% | 4; 8 and 4 µM |
|
|
| AcrAP2 | Not calculated for 30% | 8; >250 and 16 µM | AcrAP2a | Not calculated for 30% | 4; 8 and 4 µM | ||
| Pin2 | 30% in ∼5 µM | 18.8 and 37.5 µM | Pin2 [G] | 30% in ∼2 µM | 12.5 and 12.5 µM |
|
|
| Pin2 [GPG] | 30% in ∼25 µM | 25 and 25 µM | |||||
| AaeAP1 | Not calculated for 30% | 16; >512 and 32 mg/L | AaeAP1a | Not calculated for 30% | 4; 16 and 4 mg/L |
|
|
| AaeAP2 | Not calculated for 30% | 16; >512 and 32 mg/L | AaeAP2a | Not calculated for 30% | 4; 1 and 4 mg/L | ||
| MK049518 | Not calculated | 6.7; >54.1 and >54.1 µM | S3K | Not calculated | 1.5; 12.6 and 12.6 µM |
|
|
| G2K–S3K | Not calculated | 1.4; 2.8 and 5.7 µM |
30% of hemolysis was considered the maximum acceptable limit.
FIGURE 3Antimicrobial peptides visualized using PyMol. (A,C) Peptide tridimensional view of TsAP-1 and TsAP-S1, respectively. (B,D) Different angles of the electrostatic surface created through Adaptive Poisson–Boltzmann solver (APBS). The negatively charged surface is shown in red, the positively charged surface is shown in blue, and the neutrally charged surface is shown in white.
FIGURE 4Schematic models of the main proposed mechanisms of action of AMPs on microorganism cellular membranes.
FIGURE 5Illustration of the main molecular targets of AMPs already described. AMP, antimicrobial peptide; TA, teichoic acid; LTA, lipoteichoic acid.
Comparison of the structure of antimicrobial peptides from scorpion venom analyzed by nuclear magnetic resonance spectroscopy.
| Peptide/references | Sequence | Equipment | Solvent | Structure |
|---|---|---|---|---|
|
| RSVCRQIKICRRRGGCYYKCTNRPY | Liquid probe—500 MHz | H2O:D2O (9:1) | β-Hairpin |
|
| IFGAIAGLLKNIF | Liquid probe—600 MHz | H2O:d3-TFE (1:1) | 61.5% α-helix |
|
| FFGHLFKLATKIIPSLFQ | Liquid probe—600 MHz | H2O:d3-TFE (1:1) | 76.4% α-helix |
|
| GRGREFMSNLKEKLSGVKEKMKNS | Liquid probe—600 MHz | H2O:d3-TFE (1:1) | 70.8% α-helix |
|
| FFSLIPSLVGGLISAFK | Liquid probe—800 MHz | H2O:d3-TFE (3:2) | 58.8% α-helix |
|
| ILGKIWEGIKSLF | Liquid probe—600 MHz | D25-SDS | 46.1% α-helix |
|
| ILGK | Liquid probe—600 MHz | D25-SDS | Random structure |
|
| ILGKIW | Liquid probe—600 MHz | D25-SDS | 84.6% α-helix |
|
| ILGKIW | Liquid probe—600 MHz | D25-SDS | 46.1% α-helix |
|
| FWGALAKGALKLIPSLFSSFSKKD | Liquid probe—500 and 600 MHz | DPC micelles | 79.1% α-helix |
|
| FLWGLIPGAISAVTSLIKK | Liquid probe—800 MHz | SDS | 73.6 α-helix |
|
| FLWGLIPGAISAVTSLIKK | Cryoprobe—800 MHz | DPC micelles | 52.6 α-helix |
|
| GKVWDWIKSAAKKIWSSEPVSQLKGQVLNAAKNYVAEKIGATPT | Solid probe—300 MHZ | PC or PC/PG vesicles | 2 α-helix separated by 8 aa in random structure |
Modifications in analog peptides are marked in bold.